These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 39407338

  • 1. Predictors of early and interim culture un-conversion in multidrug-resistant/rifampicin-resistant tuberculosis: a retrospective multi-center cohort study in China.
    Chen Q, He W, Du J, Kang W, Zou L, Tang X, Tang P, Guo C, Pan Q, Zhu Q, Yang S, Guo Z, Wu G, Tang S.
    Antimicrob Resist Infect Control; 2024 Oct 15; 13(1):126. PubMed ID: 39407338
    [Abstract] [Full Text] [Related]

  • 2. Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study.
    Franke MF, Khan P, Hewison C, Khan U, Huerga H, Seung KJ, Rich ML, Zarli K, Samieva N, Oyewusi L, Nair P, Mudassar M, Melikyan N, Lenggogeni P, Lecca L, Kumsa A, Khan M, Islam S, Hussein K, Docteur W, Chumburidze N, Berikova E, Atshemyan H, Atwood S, Alam M, Ahmed S, Bastard M, Mitnick CD.
    Am J Respir Crit Care Med; 2021 Jan 01; 203(1):111-119. PubMed ID: 32706644
    [Abstract] [Full Text] [Related]

  • 3. Bedaquiline versus injectable containing regimens for rifampicin-resistant and multidrug-resistant tuberculosis in a reference center in Brazil - a real-world evidence study using a retrospective design.
    Santos AP, Benace CJ, de Medeiros Leung JA, Kritski AL, de Queiroz Mello FC.
    BMC Infect Dis; 2024 Oct 07; 24(1):1112. PubMed ID: 39375590
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis.
    Mbuagbaw L, Guglielmetti L, Hewison C, Bakare N, Bastard M, Caumes E, Fréchet-Jachym M, Robert J, Veziris N, Khachatryan N, Kotrikadze T, Hayrapetyan A, Avaliani Z, Schünemann HJ, Lienhardt C.
    Emerg Infect Dis; 2019 May 07; 25(5):936-943. PubMed ID: 31002070
    [Abstract] [Full Text] [Related]

  • 9. Prevalence, Predictors, and Successful Treatment Outcomes of Xpert MTB/RIF-identified Rifampicin-resistant Tuberculosis in Post-conflict Eastern Democratic Republic of the Congo, 2012-2017: A Retrospective Province-Wide Cohort Study.
    Bulabula ANH, Nelson JA, Musafiri EM, Machekano R, Sam-Agudu NA, Diacon AH, Shah M, Creswell J, Theron G, Warren RM, Jacobson KR, Chirambiza JP, Kalumuna D, Bisimwa BC, Katoto PDMC, Kaswa MK, Birembano FM, Kitete L, Grobusch MP, Kashongwe ZM, Nachega JB.
    Clin Infect Dis; 2019 Sep 27; 69(8):1278-1287. PubMed ID: 30759187
    [Abstract] [Full Text] [Related]

  • 10. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome.
    Holtz TH, Sternberg M, Kammerer S, Laserson KF, Riekstina V, Zarovska E, Skripconoka V, Wells CD, Leimane V.
    Ann Intern Med; 2006 May 02; 144(9):650-9. PubMed ID: 16670134
    [Abstract] [Full Text] [Related]

  • 11. Clinical outcomes of multidrug-resistant tracheobronchial tuberculosis receiving anti-tuberculosis regimens containing bedaquiline or delamanid.
    Chen Q, Huang T, Zou L, Tang X, Shi Z, Wang X, Wu H, Sun J, Lu X, Liang L, Jiang L, Liu D, Tang S, Wu G, He W.
    Sci Rep; 2024 Jul 29; 14(1):17347. PubMed ID: 39069547
    [Abstract] [Full Text] [Related]

  • 12. Factors associated with time to sputum culture conversion of rifampicin-resistant tuberculosis patients in Klaipeda, Lithuania in 2016-2019: a cohort study.
    Diktanas S, Korotych O, Sereda Y, Gozalov O, Rubcova O, Achar J.
    Monaldi Arch Chest Dis; 2021 Jan 14; 91(1):. PubMed ID: 33470085
    [Abstract] [Full Text] [Related]

  • 13. Strong Increase in Moxifloxacin Resistance Rate among Multidrug-Resistant Mycobacterium tuberculosis Isolates in China, 2007 to 2013.
    Xia H, Zheng Y, Liu D, Wang S, He W, Zhao B, Song Y, Ou X, Zhou Y, van den Hof S, Cobelens F, Zhao Y.
    Microbiol Spectr; 2021 Dec 22; 9(3):e0040921. PubMed ID: 34851179
    [Abstract] [Full Text] [Related]

  • 14. Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study.
    Bonnet M, Bastard M, du Cros P, Khamraev A, Kimenye K, Khurkhumal S, Hayrapetyan A, Themba D, Telnov A, Sanchez-Padilla E, Hewison C, Varaine F.
    Int J Tuberc Lung Dis; 2016 Feb 22; 20(2):177-86. PubMed ID: 26792469
    [Abstract] [Full Text] [Related]

  • 15. Sputum culture reversion in longer treatments with bedaquiline, delamanid, and repurposed drugs for drug-resistant tuberculosis.
    Kho S, Seung KJ, Huerga H, Bastard M, Khan PY, Mitnick CD, Rich ML, Islam S, Zhizhilashvili D, Yeghiazaryan L, Nikolenko EN, Zarli K, Adnan S, Salahuddin N, Ahmed S, Vargas ZHR, Bekele A, Shaimerdenova A, Tamirat M, Gelin A, Vilbrun SC, Hewison C, Khan U, Franke M.
    Nat Commun; 2024 May 09; 15(1):3927. PubMed ID: 38724531
    [Abstract] [Full Text] [Related]

  • 16. Unacceptable treatment outcomes and associated factors among India's initial cohorts of multidrug-resistant tuberculosis (MDR-TB) patients under the revised national TB control programme (2007-2011): Evidence leading to policy enhancement.
    Parmar MM, Sachdeva KS, Dewan PK, Rade K, Nair SA, Pant R, Khaparde SD.
    PLoS One; 2018 May 09; 13(4):e0193903. PubMed ID: 29641576
    [Abstract] [Full Text] [Related]

  • 17. Twenty-four-week interim outcomes of bedaquiline-containing regimens in treatment of adolescents with rifampicin-resistant tuberculosis: A retrospective cohort study in China.
    Wu HY, Tian Y, Wang XD, Sun JS, Fan LC, Chen MX, Li R, Chen Y.
    J Paediatr Child Health; 2022 Jan 09; 58(1):116-121. PubMed ID: 34323328
    [Abstract] [Full Text] [Related]

  • 18. Effectiveness and safety of bedaquiline under conditional access program for treatment of drug-resistant tuberculosis in India: An interim analysis.
    Salhotra VS, Sachdeva KS, Kshirsagar N, Parmar M, Ramachandran R, Padmapriyadarsini C, Patel Y, Mehandru L, Jaju J, Ponnuraja C, Gupta M, Kalaiselvan V, Shamim A, Khaparde S, Swaminathan S, Bedaquiline CAP Site Teams.
    Indian J Tuberc; 2020 Jan 09; 67(1):29-37. PubMed ID: 32192613
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of six months sputum culture conversion as a surrogate endpoint in a multidrug resistant-tuberculosis trial.
    Meyvisch P, Kambili C, Andries K, Lounis N, Theeuwes M, Dannemann B, Vandebosch A, Van der Elst W, Molenberghs G, Alonso A.
    PLoS One; 2018 Jan 09; 13(7):e0200539. PubMed ID: 30024924
    [Abstract] [Full Text] [Related]

  • 20. Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis.
    Chang KC, Leung CC, Yew WW, Leung EC, Leung WM, Tam CM, Zhang Y.
    Antimicrob Agents Chemother; 2012 Nov 09; 56(11):5465-75. PubMed ID: 22869570
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.